Joseph Schwartz
Stock Analyst at Leerink Partners
(1.69)
# 3,115
Out of 4,735 analysts
142
Total ratings
32.52%
Success rate
-2.39%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Outperform | $20 → $40 | $18.37 | +117.75% | 6 | Oct 11, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $11 → $14 | $0.65 | +2,043.95% | 2 | Sep 19, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Market Perform | $4 | $3.96 | +1.01% | 3 | Sep 12, 2024 | |
| ANTX AN2 Therapeutics | Upgrades: Outperform | n/a | $1.27 | - | 3 | Jul 3, 2024 | |
| SLDB Solid Biosciences | Upgrades: Outperform | $12 | $3.27 | +266.97% | 6 | Jun 24, 2024 | |
| MREO Mereo BioPharma Group | Maintains: Outperform | $6 → $8 | $2.86 | +179.72% | 2 | Jun 20, 2024 | |
| RGLS Regulus Therapeutics | Initiates: Outperform | $6 | $1.24 | +383.87% | 2 | Mar 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Market Perform | $9 → $2 | $0.36 | +448.25% | 5 | Mar 14, 2024 | |
| SYBX Synlogic | Downgrades: Market Perform | $1 | $1.46 | -31.51% | 4 | Feb 9, 2024 | |
| DSGN Design Therapeutics | Downgrades: Market Perform | $6 | $5.06 | +18.58% | 4 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $43.84 | +9.49% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $18.36 | -1.96% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $20 | $8.30 | +140.96% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $31.43 | +8.18% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $122 → $130 | $61.53 | +111.28% | 10 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $160 | $118.00 | +35.59% | 13 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $128.13 | +27.21% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $0.96 | +939.61% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $2.30 | +1,334.78% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $12 | $8.01 | +49.81% | 6 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $108 | $40.00 | +170.00% | 6 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $50 | $72.51 | -31.04% | 3 | Oct 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $39 | $37.35 | +4.42% | 1 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $4 | $2.54 | +57.48% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $26.26 | +14.24% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $50 | $28.92 | +72.89% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $36.82 | -18.52% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $56 | $14.05 | +298.58% | 1 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $9.41 | +48.78% | 12 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.37 | +406.33% | 2 | Sep 26, 2017 |
Travere Therapeutics
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $18.37
Upside: +117.75%
Applied Therapeutics
Sep 19, 2024
Maintains: Outperform
Price Target: $11 → $14
Current: $0.65
Upside: +2,043.95%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Market Perform
Price Target: $4
Current: $3.96
Upside: +1.01%
AN2 Therapeutics
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.27
Upside: -
Solid Biosciences
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $3.27
Upside: +266.97%
Mereo BioPharma Group
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $2.86
Upside: +179.72%
Regulus Therapeutics
Mar 18, 2024
Initiates: Outperform
Price Target: $6
Current: $1.24
Upside: +383.87%
Spruce Biosciences
Mar 14, 2024
Downgrades: Market Perform
Price Target: $9 → $2
Current: $0.36
Upside: +448.25%
Synlogic
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.46
Upside: -31.51%
Design Therapeutics
Aug 15, 2023
Downgrades: Market Perform
Price Target: $6
Current: $5.06
Upside: +18.58%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $43.84
Upside: +9.49%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $18.36
Upside: -1.96%
Feb 3, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $8.30
Upside: +140.96%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $31.43
Upside: +8.18%
Feb 3, 2023
Maintains: Outperform
Price Target: $122 → $130
Current: $61.53
Upside: +111.28%
Jan 20, 2023
Reiterates: Outperform
Price Target: $160
Current: $118.00
Upside: +35.59%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $128.13
Upside: +27.21%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $0.96
Upside: +939.61%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $2.30
Upside: +1,334.78%
Nov 4, 2022
Maintains: Outperform
Price Target: $17 → $12
Current: $8.01
Upside: +49.81%
Nov 3, 2022
Maintains: Outperform
Price Target: $115 → $108
Current: $40.00
Upside: +170.00%
Oct 27, 2022
Maintains: Outperform
Price Target: $52 → $50
Current: $72.51
Upside: -31.04%
May 26, 2022
Maintains: Outperform
Price Target: $36 → $39
Current: $37.35
Upside: +4.42%
May 12, 2022
Maintains: Outperform
Price Target: $6 → $4
Current: $2.54
Upside: +57.48%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $26.26
Upside: +14.24%
May 11, 2022
Maintains: Outperform
Price Target: $53 → $50
Current: $28.92
Upside: +72.89%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $36.82
Upside: -18.52%
May 3, 2022
Maintains: Outperform
Price Target: $71 → $56
Current: $14.05
Upside: +298.58%
Feb 24, 2022
Maintains: Outperform
Price Target: $16 → $14
Current: $9.41
Upside: +48.78%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.37
Upside: +406.33%